Pharmaceutical company compliance officers support having board members certify compliance programs but would like more flexibility in monitoring corporate activities and in the reviews conducted by independent review organizations.
These are some of the findings that came out of a government-industry pharmaceutical compliance roundtable discussion that HHS’ Office of Inspector General convened in February. The attendees included 42 compliance...